Niklas Loman

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

M. William Audeh, James Carmichael, Richard T. Penson et al. · The Lancet · 2010 · 2.3K citations

Medicine, Gynecology, Oncology +16

Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation

Bella Kaufman, Ronnie Shapira‐Frommer, Rita K. Schmutzler et al. · Journal of Clinical Oncology · 2014 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +17

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression

Asís Palazón, Petros A. Tyrakis, David Macías et al. · Cancer Cell · 2017 · 530 citations · Full text

Medicine, Cancer Biology, Oncology +17

Association of Type and Location of<i>BRCA1</i>and<i>BRCA2</i>Mutations With Risk of Breast and Ovarian Cancer

Timothy R. Rebbeck, Nandita Mitra, Fei Wan et al. · JAMA · 2015 · 509 citations · Full text

Medicine, Genetics, Oncology +17